Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study.

摘要: Objectives/Hypothesis: Since the concept of tinnitus dopaminergic pathway emerged, studies have been proposed to investigate if agents influence tinnitus. We hypothesized that pramipexole, an agonist on D2/D3 receptors, may antagonize in presbycusis patients (in frequency range 250 8,000 Hz) a dose schedule accepted for treatment Parkinson's disease elderly people. Study Design: We designed randomized, prospective, placebo-controlled and double-blind trial. Methods: Forty aged 50 years or older with subjective were randomized two groups (20 both). Patients drug group took pramipexole over period 4 weeks according as follows: week 1, 0.088 mg t.i.d.; 2, 0.18 3, 0.7 4, t.i.d. 3 days rest week. second received placebo. Determination grading perception, handicap inventory (THI) questionnaire electrocochleography (ECOG) examinations served end points. Subjective audiometry was used produce secondary data. A significant improvement annoyance is found treated versus placebo respect inhibition decrease loudness greater than 30 dB. However, neither ECOG nor pure-tone threshold revealed any change hearing response either placebo. Conclusions: Pramipexole effective agent against associated at disease. The did not threshold. Laryngoscope, 2011